Cargando…

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice

PURPOSE: Among chronic liver diseases, non-alcoholic fatty liver disease (NAFLD) is one of the commonest. Although empagliflozin has several therapeutic uses in treating cardiovascular and renal disorders, its impacts and mechanisms on NAFLD are poorly understood. This research aimed to examine the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niu, Shu, Ren, Qingjuan, Chen, Shuchun, Pan, Xiaoyu, Yue, Lin, Chen, Xing, Li, Zelin, Zhen, Ruoxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461752/ https://www.ncbi.nlm.nih.gov/pubmed/37645238 http://dx.doi.org/10.2147/DMSO.S422327

Ejemplares similares

Effect of high-fat diet and empagliflozin on cardiac proteins in mice
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
por: Chen, Xing, et al.
Publicado: (2022)

Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice
por: Yue, Lin, et al.
Publicado: (2022)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum]
Publicado: (2023)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
por: Niu, Shu, et al.
Publicado: (2022)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
por: Ren, Qingjuan, et al.
Publicado: (2022)

UTP14A, DKC1, DDX10, PinX1, and ESF1 Modulate Cardiac Angiogenesis Leading to Obesity-Induced Cardiac Injury
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Effect of empagliflozin on cytoskeletal repair in the hippocampus of obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2022)

Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Song, Tiantian, et al.
Publicado: (2021)

Correlation of Body Mass Index with Clinicopathologic Parameters in Patients with Idiopathic Membranous Nephropathy
por: Chen, Xing, et al.
Publicado: (2022)

The Combination of Remnant Cholesterol and Waist Circumference Offers Predictive Value for Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study from a Medical Examination Center
por: Jia, Zhuoya, et al.
Publicado: (2023)

Hepatic transcriptome signatures in mice and humans with nonalcoholic fatty liver disease
por: Ding, Yiming, et al.
Publicado: (2023)

Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhang, Yuyuan, et al.
Publicado: (2022)

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
por: Ma, Yuting, et al.
Publicado: (2021)

Mechanisms of Small Intestine Involvement in Obesity-Induced Atherosclerosis
por: Pan, Xiaoyu, et al.
Publicado: (2023)

Hepatic Innervations and Nonalcoholic Fatty Liver Disease
por: Adori, Monika, et al.
Publicado: (2023)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

A correlation study of the relationships between nonalcoholic fatty liver disease and serum triglyceride concentration after an oral fat tolerance test
por: Hou, Xiaoyu, et al.
Publicado: (2021)

Silibinin improves nonalcoholic fatty liver by regulating the expression of miR-122: An in vitro and in vivo study
por: Yang, Liying, et al.
Publicado: (2021)

Serum Cortistatin Level in Type 2 Diabetes Mellitus and Its Relationship with Nonalcoholic Fatty Liver Disease
por: Sun, Tiantian, et al.
Publicado: (2023)

Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
por: Wang, Xin, et al.
Publicado: (2011)

The Correlation Between Estimated Glucose Disposal Rate and Coagulation Indexes in Type 2 Diabetes Mellitus
por: Li, Zelin, et al.
Publicado: (2022)

Correlation between Cardiac Ultrasound Index and Cardiovascular Risk in Healthy Obese and Overweight Populations
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Correlation of Obesity and Overweight with Cervical Vascular Function Among Healthy Populations
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease
por: Ran, Li-Sha, et al.
Publicado: (2022)

The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice
por: Sun, Qin-Juan, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
por: Koo, Seung-Hoi
Publicado: (2013)

Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease
por: Shigiyama, Fumika, et al.
Publicado: (2017)

The Relationship Between Non-HDL-C /HDL-C Ratio (NHHR) and Vitamin D in Type 2 Diabetes Mellitus
por: Zhen, Ruoxi, et al.
Publicado: (2023)

Myeloid-specific blockade of Notch signaling ameliorates nonalcoholic fatty liver disease in mice
por: Ding, Jian, et al.
Publicado: (2023)

Indole-3-Acetic Acid Alleviates Nonalcoholic Fatty Liver Disease in Mice via Attenuation of Hepatic Lipogenesis, and Oxidative and Inflammatory Stress
por: Ji, Yun, et al.
Publicado: (2019)

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease
por: Zhou, Fangli, et al.
Publicado: (2021)

Macrophage metabolism in nonalcoholic fatty liver disease
por: Zhang, Wenhui, et al.
Publicado: (2023)

Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
por: Ma, Yuting, et al.
Publicado: (2022)

Serum folate associated with nonalcoholic fatty liver disease and advanced hepatic fibrosis
por: Chen, Hao-Kai, et al.
Publicado: (2023)

Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B
por: Zhang, Siyu, et al.
Publicado: (2023)

Vegetarian diet, food substitution, and nonalcoholic fatty liver
por: Chiu, Tina H., et al.
Publicado: (2018)

Lycium ruthenicum Murr. alleviates nonalcoholic fatty liver in mice
por: Lu, Keke, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8m533ncnckqio7qgo389m5tn6k